XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

ASSET ACQUISITION (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] |
Summary of Asset Acquisition | The following summarizes the total consideration transferred and allocation to the assets acquired, liabilities assumed and acquired IPR&D:
Cash consideration for outstanding shares | $ | 260,424 |
Cash consideration for equity awards | 9,950 |
Consideration paid to Inozyme | 270,374 |
Repayment of Inozyme debt | 49,095 |
Employee-related incentive payments | 2,714 |
Transaction costs | 6,950 |
Total consideration | $ | 329,133 |
Cash and cash equivalents | $ | 43,939 |
Other assets | 10,779 |
Deferred tax assets | 68,697 |
Other liabilities | (15,245) |
Total identifiable assets acquired, net | 108,170 |
Acquired IPR&D | 220,963 |
Total assets and liabilities | $ | 329,133 |

X
- Definition Tabular disclosure of asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration